Our Take
Most of these candidates are still in preclinical or late preclinical stages; the real test is whether injectable nanoclays, potassium permanganate patches, and iPSC therapies clear Phase trials on the timelines claimed.
Why it matters
Chronic wounds cost $400 billion annually with 90% spent on labor, not drugs. If any of these platforms reduce healing time or labor burden materially, the market opportunity and reimbursement pressure will intensify fast.
Do this week
Clinical teams: flag these four companies and their 2027–2028 trial start dates for competitive landscape review so you're not blindsided by positive Phase II data.
Four European Biotech Companies Presented Clinical Candidates and Delivery Platforms
At BioTrinity 2026, organized by BioUK, European biotech companies showcased cell therapies, protein biologics, and novel delivery methods targeting chronic wounds and ophthalmic disease. The standout presentations came from four spin-outs or early-stage firms, each with a lead clinical candidate and a defined trial entry date.
Renovos Biologics (University of Southampton spin-out) is developing an injectable, biodegradable synthetic nanoclay called RENOVITE for use with bone morphogenetic protein 2 (BMP-2) in spinal fusion procedures. Current BMP-2 formulations are poorly retained around the spine, leading to off-target bone growth and inflammation; the company's nanoclay localizes the protein and allows delivery via a 23-gauge needle in lower doses. RENOVITE BMP-2 is expected to enter first-in-human trials by 2027 (company-reported). The spinal fusion market is projected to reach $24.5 billion by 2035, with 21% of lumbar fusions performed on patients under 45 years old.
Onya Therapeutics (Ebbw Vale, U.K.) closed a £2.6 million seed round in 2025 and is developing OTX-PP01, an adhesive patch based on potassium permanganate, a compound with over 150 years of clinical safety data. The patch is applied for 15 minutes to reduce excessive wound exudate through astringent and antimicrobial action, targeting the inflammatory cycle that stalls healing. Onya is pursuing a Phase II/III adaptive trial design for diabetic foot ulcers, venous leg ulcers, and pressure ulcers, aiming to complete enrollment within four to five years. The company did not need to conduct Phase I studies owing to the established safety profile of its active compound.
StemSight (Tampere, Finland) is developing STE-101, an allogeneic limbal stem cell therapy using gene-edited iPSCs to treat limbal stem cell deficiency (LSCD), a rare disease affecting over 240,000 patients worldwide and currently treatable only in patients with one healthy eye. The company can produce 100 patient doses per batch under GMP-compliant manufacturing. STE-101 has shown efficacy in rodent models for regenerating corneal epithelium; Phase I/II trials are planned to begin early 2028 (company-reported).
Link Biologics (University of Manchester spin-out) is developing TSG-6–based protein biologics for dry eye disease (DED) and wet age-related macular degeneration (AMD). The lead candidate, LB001, combines anti-inflammatory and tissue-repair activity in preclinical mouse models, where twice-daily dosing for seven days reduced corneal damage and inflammatory markers compared to branded cyclosporine (Restasis). Link has completed chemistry, manufacturing, and controls work and plans to initiate a 180-patient Phase I/II trial in 2027 (company-reported).
The Real Opportunity Is Labor Cost, Not Drug Cost
Chronic wounds represent a $400 billion global burden, with 90% of costs attributed to wound management labor and only 6% to the products themselves (company-reported). Diabetic foot ulcers result in limb loss within five years in 30% of patients. The market is called an innovation desert because existing therapies are difficult to scale and adapt.
Each of these four companies is pursuing a different mechanism: retaining growth factors in situ, suppressing inflammatory exudate, regenerating lost epithelium, and enhancing endogenous tissue repair. If any of them materially shortens healing time or reduces nursing burden, the reimbursement calculus shifts sharply. Current standard-of-care comparators (cyclosporine for DED, conventional BMP-2 for spinal fusion, absorbent dressings for chronic wounds) set a low bar.
The cohort also reflects a broader trend: use of established, off-patent molecules (potassium permanganate, TSG-6) in novel delivery formats to bypass Phase I and accelerate to clinical efficacy data. This is not a shortcut but a rational path when safety is already known.
Trial Timeline and Manufacturing Risk Are the Key Variables
All four companies have committed to trial entry between late 2027 and early 2028. The critical unknowns are enrollment pace, efficacy signal, and manufacturing scale. StemSight and Link both report GMP-compliant processes, but StemSight's frozen cell-banking model and Link's eye drop formulation stability claim require verification once trials launch.
For Renovos and Onya, the regulatory pathway is clearer (BMP-2 is established, potassium permanganate has 150 years of use), but retention of protein and consistency of therapeutic benefit in human patients remain unproven. The nanoclay's biodegradation kinetics and the patch's 15-minute contact time are design claims, not yet clinical validation.
Onya's £2.6 million seed is notably small for a Phase II/III program; future financing risk is material. Link and StemSight have not disclosed recent funding, and neither has announced a lead investor or partnership, raising questions about capital sufficiency for multi-year trials.